Lazard Upgrades Valeant Pharma (VRX) to Hold
More News related to VRX
- Notable Analyst Rating Changes 6/9: X, CSX, OMTR, MRVL Higher; HIG, VRX, MAS Lower
- Penwest Pharma (PPCO, Endo Pharma (ENDP) Grant Valeant (VRX) Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
- Wachovia Downgrades Valeant Pharmaceuticals (VRX) to Underperform; Risk/Reward Unfavorable
- Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(r) ER in Canada, Australia and New Zealand
- Valeant Announces Pricing of Senior Notes
More News related to Upgrades
- Morgan Joseph Upgrades Central European Media Enterprises (CETV) to Buy; Financial Risk Mitigated
- FormFactor (FORM): Upgraded to Outperform at Oppenheimer; $30 target
- Cowen & Co Upgrades VeriSign (VRSN) to Outperform
- Deutsche Bank Upgrades Symantec (SYMC) to Buy; Compelling Risk/Reward Opportunity
- Bank of Ameria Upgrades Tomkins plc (TKS) to Buy
Lazard Capital upgrades Valeant Pharmaceuticals (NYSE: VRX) from Sell to Hold.
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products.
Related Categories
UpgradesStocks Mentioned
+0.41Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
